Pasar al contenido principal

MECANISMOS ALLOSTERICOS PARA LA MODULACION DE RECEPTORES ACOPLADOS A PROTEINAS G RELACIONADOS CON DOLOR Y OBESIDAD

PID2022-140912OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Allosterism in the adenosine A2A and cannabinoid CB2 heteromer

  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Raïch, Iu|||0000-0001-6271-0495
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Lillo Jové, Jaume|||0000-0001-7712-0850
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Franco, Rafael|||0000-0003-2549-4919
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
Background and Purpose: Allosterism is a regulatory mechanism for GPCRs that can be attained by ligand-binding or protein-protein interactions with another GPCR. We have studied the influence of the dimer interface on the allosteric properties of the A2A receptor and CB2 receptor heteromer. Experimental Approach: We have evaluated cAMP production, phosphorylation of signal-regulated kinases (pERK1/2), label-free dynamic mass redistribution, β-arrestin 2 recruitment and bimolecular fluorescence complementation assays in the absence and presence of synthetic peptides that disrupt the formation of the heteromer. Molecular dynamic simulations provided converging evidence that the heteromeric interface influences the allosteric properties of the A2AR-CB2R heteromer. Key Results: Apo A2AR blocks agonist-induced signalling of CB2R. The disruptive peptides, with the amino acid sequence of transmembrane (TM) 6 of A2AR or CB2R, facilitate CB2R activation, suggesting that A2AR allosterically prevents the outward movement of TM 6 of CB2R for G protein binding. Significantly, binding of the selective antagonist SCH 58261 to A2AR also facilitated agonist-induced activation of CB2R. Conclusions and Implications: It is proposed that the A2AR-CB2R heteromer contains distinct dimerization interfaces that govern its functional properties. The molecular interface between protomers of the A2AR-CB2R heteromer interconverted from TM 6 for apo or agonist-bound A2AR, blocking CB2R activation, to mainly the TM 1/7 interface for antagonist-bound A2AR, facilitating the independent opening of intracellular cavities for G protein binding. These novel results shed light on a different type of allosteric mechanism and extend the repertoire of GPCR heteromer signalling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Leu/Val6.51 Side Chain of Cannabinoid Receptors Regulates the Binding Mode of the Alkyl Chain of Δ9-Tetrahydrocannabinol

  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Raïch, Iu|||0000-0001-6271-0495
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Lillo, Jaume
  • Rebassa, Joan Biel
  • Ferreiro-Vera, Carlos
  • Sánchez de Medina, Verónica
  • Franco, Rafael|||0000-0003-2549-4919
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
(-)-Δ-trans-tetrahydrocannabinol (THC), which is the principal psychoactive constituent of Cannabis, mediates its action by binding to two members of the G-protein-coupled receptor (GPCR) family: the cannabinoid CB (CBR) and CB (CBR) receptors. Molecular dynamics simulations showed that the pentyl chain of THC could adopts an I-shape conformation, filling an intracellular cavity between Phe and Trp for initial agonist-induced receptor activation, in CBR but not in CBR. This cavity opens to the five-carbon chain of THC by the conformational change of the γ-branched, flexible, Leu side chain of CBR, which is not feasible by the β-branched, mode rigid, Val side chain of CBR. In agreement with our computational results, THC could not decrease the forskolin-induced cAMP levels in cells expressing mutant CBR receptor but could activate the mutant CBR receptor as efficiently as wild-type CBR. Additionally, JWH-133, a full CBR agonist, contains a branched dimethyl moiety in the ligand chain that bridges Phe and Val for receptor activation. In this case, the substitution of Val to Leu in CBR makes JWH-133 unable to activate CBR. In conclusion, our combined computational and experimental results have shown that the amino acid at position 6.51 is a key additional player in the initial mechanism of activation of GPCRs that recognize signaling molecules derived from lipid species.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design of Small Non-Peptidic Ligands That Alter Heteromerization between Cannabinoid CB and Serotonin 5HT Receptors

  • Matsoukas, Minos-Timotheos|||0000-0002-4642-8163
  • Ciruela-Jardí, Marc|||0009-0001-9920-8789
  • Gallo, Maria|||0000-0001-9099-7235
  • Ferré, Sergi|||0000-0002-1747-1779
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Casadó, Vicent|||0000-0002-1764-3825
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Moreno, Estefanía|||0000-0002-2491-5753
Activation of cannabinoid CB receptors (CBR) by agonists induces analgesia but also induces cognitive impairment through the heteromer formed between CBR and the serotonin 5HT receptor (5HTR). This side effect poses a serious drawback in the therapeutic use of cannabis for pain alleviation. Peptides designed from the transmembrane helices of CBR, which are predicted to bind 5HTR and alter the stability of the CBR-5HTR heteromer, have been shown to avert CBR agonist-induced cognitive impairment while preserving analgesia. Using these peptides as templates, we have now designed nonpeptidic small molecules that prevent CBR-5HTR heteromerization in bimolecular fluorescence complementation assays and the heteromerization-dependent allosteric modulations in cell signaling experiments. These results provide proof-of-principle for the design of optimized ligand-based disruptors of the CBR-5HTR heteromer, opening new perspectives for in vivo studies.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Mechanism of μ-opioid receptor inhibition by orphan GPR88

  • Llinas del Torrent, Claudia
  • Raïch, Iu
  • Carrasco-Martinez, Berta
  • Lillo, Jaume
  • Gallo, María, 1989-
  • Andreu Martínez, David
  • Pardo Carrasco, Leonardo
  • Navarro, Gemma
From the approximately 800 members of the G protein-coupled receptor (GPCR) family, more than 100 remain orphans (oGPCRs). There is evidence indicating that some oGPCRs may carry out a physiological role independently from endogenous ligands; this includes forming heteromers with other GPCRs and altering their functional and pharmacological properties via allosteric interactions. Recent studies have shown that some of these oGPCRs, e.g. GPR88 and GPR139, allosterically inhibit opioid activity by interacting with the μ-opioid receptor (μOR). Here, we have focused on the characterization of the interaction between GPR88 and µOR and the allosteric mechanism of inhibition. We confirmed that GPR88 inhibits µOR function in striatal neuronal primary cultures. Moreover, using a peptide-interfering approach combined with biophysical and biochemical techniques, we identified that GPR88 and µOR interact via transmembrane helix 6. A combination of molecular dynamic simulations and site-directed mutagenesis have allowed to propose that the negative regulatory role of GPR88 on µOR is due to the Q2986.49 side chain of GPR88., We acknowledge the financial support from the Spanish Ministry of Economy and Innovation with FEDER funds (PID2020-113430RB-I00, PID2022-140912OB-I00) and Generalitat de Catalunya (2021 SGR 00304). Work at MELIS-UPF supported by MCIN "María de Maeztu" program for units of excellence in R&D (CEX2018-000792-M). C.L.T. is recipient of a FPI Fellowship (BES-2017-081872) and B.C-M. is recipient of a FI Fellowship (2025 FI-1 00603). The authors thankfully acknowledge the computer resources at MareNostrum and the technical support provided by Barcelona Supercomputing Center (RES-BCV2025-1-0011).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Design of small non-peptidic ligands that alter heteromerization between cannabinoid CB1 and serotonin 5HT2A receptors

  • Matsoukas, Minos-Timotheos
  • Ciruela Jardí, Marc
  • Gallo, María, 1989-
  • Ferré, Sergi
  • Andreu Martínez, David
  • Casadó, Vicent
  • Pardo, Leonardo
  • Moreno, Estefanía
Activation of cannabinoid CB1 receptors (CB1R) by agonists induces analgesia but also induces cognitive impairment through the heteromer formed between CB1R and the serotonin 5HT2A receptor (5HT2AR). This side effect poses a serious drawback in the therapeutic use of cannabis for pain alleviation. Peptides designed from the transmembrane helices of CB1R, which are predicted to bind 5HT2AR and alter the stability of the CB1R-5HT2AR heteromer, have been shown to avert CB1R agonist-induced cognitive impairment while preserving analgesia. Using these peptides as templates, we have now designed nonpeptidic small molecules that prevent CB1R-5HT2AR heteromerization in bimolecular fluorescence complementation assays and the heteromerization-dependent allosteric modulations in cell signaling experiments. These results provide proof-of-principle for the design of optimized ligand-based disruptors of the CB1R-5HT2AR heteromer, opening new perspectives for in vivo studies., We acknowledge the financial support from the Spanish Ministry of Economy and Innovation with FEDER funds (projects PID2020-113938RB-I00, PID2022-140912OB-I00, and PID2023-146914OB-I00) and Generalitat de Catalunya (2021-SGR-00230 and 2021-SGR-00304). S.F. is funded with the intramural funds of the National Institute on Drug Abuse (ZIA DA000493). Work at MELIS-UPF is supported by the MCIN “María de Maeztu” program for units of excellence in R&D (CEX2018-000792-M). The authors thankfully acknowledge the computer resources at MareNostrum and the technical support provided by the Barcelona Supercomputing Center (RES-BCV-2024-2-0002).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling

  • Navarro, Gemma
  • Gómez-Autet, Marc
  • Morales, Paula
  • Biel Rebassa, Joan
  • Llinas del Torrent, Claudia
  • Jagerovic, Nadine
  • Pardo, Leonardo
  • Franco, Rafael
G protein-coupled receptors (GPCRs) exist within a landscape of interconvertible conformational states and in dynamic equilibrium between monomers and higher-order oligomers, both influenced by ligand binding. Here, we show that a homobivalent ligand formed by equal chromenopyrazole moieties as pharmacophores, connected by 14 methylene units, can modulate the dynamics of the cannabinoid CB2 receptor (CB2R) homodimerization by simultaneously binding both protomers of the CB2R-CB2R homodimer. Computational and pharmacological experiments showed that one of the ligand pharmacophores binds to the orthosteric site of one protomer, and the other pharmacophore to a membrane-oriented pocket between transmembranes 1 and 7 of the partner protomer. This results in unique pharmacological properties, including increased potency in Gi-mediated signaling and enhanced recruitment of β-arrestin. Thus, by modulating dimerization dynamics, it may be possible to fine-tune CB2R activity, potentially leading to improved therapeutic outcomes, We acknowledge the financial support from the Spanish Ministry of Science and Innovation with FEDER funds (PID2020-113430RB-I00, PID2021-126600OB-I00, PDC2022-133171-I00, PID2022-140912OB- I00, PID2021-127833OB-I00, PID2022-139197OA-I00) and Generalitat de Catalunya (2021 SGR 00304). C.L.T. is recipient of a FPI fellowship (BES-2017-081872) and M.G.-A. acknowledges the Universitat Autonoma de Barcelona for his predoctoral grant., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Design of small non-peptidic ligands that alter heteromerization between cannabinoid CB1 and serotonin 5HT2A receptors

  • Matsoukas, Minos-Timotheos
  • Ciruela Jardí, Marc
  • Gallo, María, 1989-
  • Ferré, Sergi
  • Andreu Martínez, David
  • Casadó, Vicent
  • Pardo, Leonardo
  • Moreno, Estefanía
Activation of cannabinoid CB1 receptors (CB1R) by agonists induces analgesia but also induces cognitive impairment through the heteromer formed between CB1R and the serotonin 5HT2A receptor (5HT2AR). This side effect poses a serious drawback in the therapeutic use of cannabis for pain alleviation. Peptides designed from the transmembrane helices of CB1R, which are predicted to bind 5HT2AR and alter the stability of the CB1R-5HT2AR heteromer, have been shown to avert CB1R agonist-induced cognitive impairment while preserving analgesia. Using these peptides as templates, we have now designed nonpeptidic small molecules that prevent CB1R-5HT2AR heteromerization in bimolecular fluorescence complementation assays and the heteromerization-dependent allosteric modulations in cell signaling experiments. These results provide proof-of-principle for the design of optimized ligand-based disruptors of the CB1R-5HT2AR heteromer, opening new perspectives for in vivo studies., We acknowledge the financial support from the Spanish Ministry of Economy and Innovation with FEDER funds (projects PID2020-113938RB-I00, PID2022-140912OB-I00, and PID2023-146914OB-I00) and Generalitat de Catalunya (2021-SGR-00230 and 2021-SGR-00304). S.F. is funded with the intramural funds of the National Institute on Drug Abuse (ZIA DA000493). Work at MELIS-UPF is supported by the MCIN “María de Maeztu” program for units of excellence in R&D (CEX2018-000792-M). The authors thankfully acknowledge the computer resources at MareNostrum and the technical support provided by the Barcelona Supercomputing Center (RES-BCV-2024-2-0002).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mechanism of μ-opioid receptor inhibition by orphan GPR88

  • Llinas del Torrent, Claudia
  • Raïch, Iu
  • Carrasco-Martinez, Berta
  • Lillo, Jaume
  • Gallo, María, 1989-
  • Andreu Martínez, David
  • Pardo Carrasco, Leonardo
  • Navarro, Gemma
From the approximately 800 members of the G protein-coupled receptor (GPCR) family, more than 100 remain orphans (oGPCRs). There is evidence indicating that some oGPCRs may carry out a physiological role independently from endogenous ligands; this includes forming heteromers with other GPCRs and altering their functional and pharmacological properties via allosteric interactions. Recent studies have shown that some of these oGPCRs, e.g. GPR88 and GPR139, allosterically inhibit opioid activity by interacting with the μ-opioid receptor (μOR). Here, we have focused on the characterization of the interaction between GPR88 and µOR and the allosteric mechanism of inhibition. We confirmed that GPR88 inhibits µOR function in striatal neuronal primary cultures. Moreover, using a peptide-interfering approach combined with biophysical and biochemical techniques, we identified that GPR88 and µOR interact via transmembrane helix 6. A combination of molecular dynamic simulations and site-directed mutagenesis have allowed to propose that the negative regulatory role of GPR88 on µOR is due to the Q2986.49 side chain of GPR88., We acknowledge the financial support from the Spanish Ministry of Economy and Innovation with FEDER funds (PID2020-113430RB-I00, PID2022-140912OB-I00) and Generalitat de Catalunya (2021 SGR 00304). Work at MELIS-UPF supported by MCIN "María de Maeztu" program for units of excellence in R&D (CEX2018-000792-M). C.L.T. is recipient of a FPI Fellowship (BES-2017-081872) and B.C-M. is recipient of a FI Fellowship (2025 FI-1 00603). The authors thankfully acknowledge the computer resources at MareNostrum and the technical support provided by Barcelona Supercomputing Center (RES-BCV2025-1-0011).
Dipòsit Digital de Documents de la UAB
Publicación Artículo preliminar (WorkingPaper)

Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone

  • Michaelides, Michael|||0000-0003-0398-4917
  • Levinstein, Marjorie|||0000-0003-4360-1503
  • De Oliveira, Paulo
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Quiroz, Cesar
  • Budinich, Reece
  • Rais, Rana
  • Rea, William
  • Ventriglia, Emilya
  • Llopart, Natàlia
  • Casadó-Anguera, Verònica|||0000-0001-8532-2954
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Walther, Donna
  • Glatfelter, Grant
  • Weinshenker, David|||0000-0002-3678-6215
  • Zarate, Carlos
  • Casadó, Vicent|||0000-0002-1764-3825
  • Baumann, Michael
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Ferré, Sergi|||0000-0002-1747-1779
(R,S)-methadone ((R,S)-MTD) is a racemic μ-opioid receptor (MOR) agonist comprised of (R)-MTD and (S)-MTD enantiomers used for the treatment of opioid use disorder (OUD) and pain. (R)-MTD is used as an OUD treatment, has high MOR potency, and is believed to mediate (R,S)-MTD's therapeutic efficacy. (S)-MTD is in clinical development as an antidepressant and is considered an N-methyl-D-aspartate receptor (NMDAR) antagonist. In opposition to this purported mechanism of action, we found that (S)-MTD does not occupy NMDARs in vivo in rats. Instead, (S)-MTD produced MOR occupancy and induced analgesia with similar efficacy as (R)-MTD. Unlike (R)-MTD, (S)-MTD was not self-administered and failed to increase locomotion or extracellular dopamine levels indicating low abuse liability. Moreover, (S)-MTD antagonized the effects of (R)-MTD in vivo and exhibited unique pharmacodynamic properties, distinct from those of (R)-MTD. Specifically, (S)-MTD acted as a MOR partial agonist with a specific loss of efficacy at the MOR-galanin 1 receptor (Gal1R) heteromer, a key mediator of the dopaminergic effects of opioids. In sum, we report novel and unique pharmacodynamic properties of (S)-MTD that are relevant to its potential mechanism of action and therapeutic use, as well as those of (R,S)-MTD.